# Bone Biologics Corp

Bone Biologics Corp is an Asset Manager based in Burlington, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Burlington, United States
- **Region:** North America
- **Address:** Burlington, MA, United States
- **Founded:** 2004
- **Assets under management:** Undisclosed
- **Website:** bonebiologics.com

## Regulatory record

- **Reports private funds:** No

## About

Bone Biologics Corp was founded in 2004 and operates as a clinical-stage medical device company headquartered in Burlington, Massachusetts. Jeffrey Frelick serves as President and Chief Executive Officer, steering a lean organization that focuses entirely on advancing Nell-1, a recombinant human protein intended to stimulate bone growth as an alternative to autograft procedures. The company's public-company structure, with shares trading on the Nasdaq Capital Market, provides its primary access to growth funding — a capital pathway markedly different from the venture-funded private orthobiologics startups that have historically dominated this niche. The firm's strategy hinges on a single platform: a recombinant Nell-1 protein delivered via a demineralized bone matrix carrier. This asset is designed for spinal fusion procedures, a market segment that was valued at approximately $7.5 billion globally in 2023 (per Grand View Research, 2024). Bone Biologics does not maintain a diversified pipeline of implantable materials like major orthopedics competitors; instead, its deployment is binary — all resources flow toward preclinical and eventual clinical validation of Nell-1 in posterolateral spinal fusion. The geographic footprint is concentrated in the United States, where the company engages with FDA regulatory pathways and academic research institutions to advance its technology. Total headcount remains small and undisclosed, consistent with a company that had approximately $3 million in cash and cash equivalents as of the first quarter of 2024 (per the firm's SEC filings, 2024). The company maintains a single headquarters in Burlington, Massachusetts, and does not operate adjacent philanthropic vehicles, real-asset arms, or co-investor clubs — the architecture has no room for diversions from the core Nell-1 program. What genuinely separates Bone Biologics from larger orthobiologics companies is its commitment to a single-molecule thesis in a field where competitors typically hedge across ceramics, allograft tissues, and synthetic polymers. This purity of pipeline — one protein, one indication pathway, one regulatory destination — creates a binary outcome profile that is uncommon even among small-cap biotech peers. The company's Nasdaq listing also subjects it to quarterly disclosure obligations, giving any institutional allocator who considers public micro-cap healthcare positions a transparent, if volatile, window into a concentrated orthobiologics bet.

## Sectors

- Medical Devices
- Healthcare Services

## People

- Jeffrey Frelick — President and Chief Executive Officer

## Questions

### Who runs investment decisions at Bone Biologics Corp?

Investment decisions at Bone Biologics are effectively capital-allocation decisions made by President and CEO Jeffrey Frelick alongside the board of directors. As a pre-revenue Nasdaq company with roughly $3 million in cash reserves as of Q1 2024, the primary investment is continued funding of the Nell-1 recombinant protein platform. External allocators who buy the stock are making a market-based investment in the firm's clinical trajectory; the company itself does not manage external capital or operate an investment committee in the family-office sense.

### How does Bone Biologics Corp source its deal flow or research pipeline?

Bone Biologics does not source external deals in the traditional allocator sense — it generates pipeline through its proprietary Nell-1 protein platform licensed from UCLA and the University of Southern California. The company's research flow depends on preclinical study results and FDA regulatory interactions. There is no external deal-sourcing function akin to that of a venture firm or fund-of-funds manager.

### Does Bone Biologics participate in fund commitments or only direct deals?

Bone Biologics does not participate in fund commitments or direct investment deals. It is a pre-revenue operating company that deploys its own corporate capital exclusively into the development of the Nell-1 bone graft substitute platform. The firm has no external allocation program and does not serve as a limited partner in third-party funds.

### What investment stages does Bone Biologics Corp typically target?

Bone Biologics is itself a pre-revenue, clinical-stage company — it is the target of potential investment, not an allocator. The firm's own clinical development is positioned between late-stage preclinical validation and preparation for human clinical trials. External investors in Bone Biologics stock are effectively making a public micro-cap healthcare wager on a single-asset orthobiologics pipeline.

## Related profiles

- [TNL Mediagene](https://altss.com/profile/tnl-mediagene)
- [Steakholder Foods](https://altss.com/profile/steakholder-foods-ltd)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/bone-biologics-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology